{"id":27094,"date":"2026-09-03T15:41:52","date_gmt":"2026-09-03T19:41:52","guid":{"rendered":"https:\/\/www.emilysentourage.org\/?p=27094"},"modified":"2026-09-03T16:14:31","modified_gmt":"2026-09-03T20:14:31","slug":"new-emilys-entourage-grant-to-fund-novel-phage-based-therapy-for-drug-resistant-infections-in-cystic-fibrosis","status":"publish","type":"post","link":"https:\/\/www.emilysentourage.org\/de\/new-emilys-entourage-grant-to-fund-novel-phage-based-therapy-for-drug-resistant-infections-in-cystic-fibrosis\/","title":{"rendered":"Neuer Zuschuss von Emily\u2019s Entourage finanziert neuartige Phagentherapie gegen resistente Infektionen bei Mukoviszidose"},"content":{"rendered":"

Inhaled bacteriophage-antibiotic combination could offer a new treatment approach for persistent, antibiotic-resistant lung infections<\/span><\/i><\/p>\n

\"\"

Emily’s Entourage (EE) has awarded its fourth 2026 Translational Research Grant to David T. Pride, MD, PhD, Professor of Pathology and Medicine at the University of California San Diego School of Medicine.<\/p><\/div>\n

Lower Merion, PA\u2014September 3, 2026\u2014<\/span>Emily\u2019s Entourage (EE), an innovative 501(c)(3) organization accelerating research for individuals with cystic fibrosis (CF) who do not benefit from current mutation-targeted therapies, is proud to announce its fourth<\/span> 2026 Translational Research Grant awarded to David T. Pride, MD, PhD, Professor of Pathology and Medicine at the University of California San Diego School of Medicine.<\/span><\/p>\n

Dr. Pride\u2019s project aims to develop a novel inhaled therapy combining bacteriophages\u2014viruses that specifically target and kill bacteria\u2014with the antibiotic meropenem to treat persistent lung infections in people with CF that are resistant to standard antimicrobial therapies.<\/span><\/p>\n

Chronic infections and the development of antibiotic resistance pose a major threat to people with CF, driving disease progression and mortality. Among the most challenging of these infections is <\/span>Achromobacter xylosoxidans<\/span><\/i>, a pathogen that can persist in the CF lung despite repeated antibiotic treatment and frequently develops multidrug-resistant (MDR) or extensively drug-resistant (XDR) profiles, leaving people with CF with limited therapeutic options.<\/span><\/p>\n

Dr. Pride and his team have identified a large and diverse collection of bacteriophages capable of targeting and killing <\/span>Achromobacter<\/span><\/i>, with activity observed across a wide range of MDR and XDR clinical isolates. Building on this work, they have made a key discovery: when certain phages are combined with the antibiotic meropenem, the two work synergistically to eliminate the bacteria, even in cases where the bacteria are initially resistant to the antibiotic. This finding suggests a new approach to treatment, in which antibiotic effectiveness may be restored through combinations with phage therapy, expanding treatment options for resistant infections.<\/span><\/p>\n

The team will investigate the biological mechanisms underlying this synergy to better understand how and why this approach is effective.<\/span><\/p>\n

\"<\/span>Achromobacter<\/span><\/i> infections are particularly difficult to treat because of their ability to develop and maintain resistance to multiple antibiotics,\u201d said Dr. Pride. \u201cBy combining bacteriophages with existing antibiotics, we have the potential to restore antibiotic activity and provide a new treatment option for people with CF who have exhausted conventional antibiotic therapies.\u201d<\/span><\/p><\/blockquote>\n

Approximately 10% of people with CF do not benefit from current CFTR modulators and often face a disproportionate burden of chronic, treatment-resistant infections. EE is committed to advancing research that addresses both the underlying genetic causes of CF and the serious issues that continue to impact those living with CF.<\/span><\/p>\n

\u201cThis project represents an innovative and urgently needed approach to addressing antibiotic-resistant infections in CF,\u201d said Chandra Ghose, PhD, Chief Scientific Officer at EE. \u201cBy leveraging the unique ability of bacteriophages to target resistant bacteria\u2014and combining them with existing antibiotics to restore their antimicrobial effects\u2014this work has the potential to expand treatment options for individuals facing some of the most difficult-to-treat infections.\u201d<\/span><\/p>\n

 <\/p><\/blockquote>\n

\u00dcber Emily's Entourage's (EE's) Zuschussprogramm<\/b><\/p>\n

Das F\u00f6rderprogramm von Emily\u2019s Entourage (EE) stellt Mittel bereit, um die Forschung und die therapeutische Entwicklung f\u00fcr Menschen mit Mukoviszidose (CF), die nicht von bestehenden mutationszielgerichteten Therapien profitieren, zu beschleunigen. EE unterst\u00fctzt eine Reihe von F\u00f6rderinstrumenten, darunter translationale Zusch\u00fcsse, kollaborative Zusch\u00fcsse und pr\u00e4klinische explorative Zusch\u00fcsse sowie Venture-Philanthropy-Investitionen.<\/span><\/p>\n

Bislang hat EE Millionen von Dollar an multidisziplin\u00e4re Teams auf der ganzen Welt vergeben und dazu beigetragen, Millionen weiterer US-Dollar an Anschlussfinanzierungen zu sichern. Um vergebene Zusch\u00fcsse anzusehen, besuchen Sie <\/span>https:\/\/www.emilysentourage.org\/awarded-grants\/<\/span><\/a>. Weitere Informationen \u00fcber die Finanzierungsm\u00f6glichkeiten von EE finden Sie unter <\/span>https:\/\/www.emilysentourage.org\/funding-opportunities\/<\/span><\/a>.<\/span><\/p>\n

\u00dcber Emily's Entourage<\/b><\/p>\n

Emily\u2019s Entourage (EE) ist eine innovative 501(c)3-Organisation, die die Forschung nach neuen Behandlungsmethoden und einer Heilung f\u00fcr Patienten in der Endphase der Mukoviszidose (CF) vorantreibt, die nicht von den derzeit verf\u00fcgbaren, auf bestimmte Mutationen ausgerichteten Therapien profitieren. Seit 2011 hat EE Forschungszusch\u00fcsse in Millionenh\u00f6he vergeben, ein Unternehmen f\u00fcr CF-Gentherapie im klinischen Stadium gegr\u00fcndet, die Patientendatenbank \u201eClinical Trial Connect\u201c (CTC) sowie ein Vermittlungsprogramm f\u00fcr klinische Studien entwickelt, um die weltweite Rekrutierung f\u00fcr klinische Studien zu beschleunigen, und weltweite Bem\u00fchungen zur F\u00f6rderung von hochwirksamer Forschung und Arzneimittelentwicklung geleitet. Die Organisation wurde in nationalen Medien vorgestellt, darunter in der New York Times, bei STAT, CNN, People und anderen. Erfahren Sie mehr unter <\/span>emilysentourage.org<\/span><\/a>.<\/span><\/p>\n

Medienkontakt<\/b><\/p>\n

Hannah Kleckner<\/span><\/p>\n

Direktor f\u00fcr Marketing und Kommunikation<\/span><\/p>\n

hannah@emilysentourage.org<\/span><\/p>\n



<\/p>","protected":false},"excerpt":{"rendered":"

Inhaled bacteriophage-antibiotic combination could offer a new treatment approach for persistent, antibiotic-resistant lung infections Lower Merion, PA\u2014September 3, 2026\u2014Emily\u2019s Entourage (EE), an innovative 501(c)(3) organization accelerating research for individuals with cystic fibrosis (CF) who do not benefit from current mutation-targeted therapies, is proud to announce its fourth 2026 Translational Research Grant awarded to David T…. <\/p>\n

<\/div>\n

Mehr lesen<\/a><\/p>","protected":false},"author":1719,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_seopress_titles_title":"New Emily\u2019s Entourage Grant to Fund Novel Phage-Based Therapy for Drug-Resistant Infections in Cystic Fibrosis","_seopress_titles_desc":"","_seopress_robots_index":"","_seopress_robots_follow":"","_seopress_robots_imageindex":"","_seopress_robots_snippet":"","_seopress_robots_primary_cat":"","_seopress_robots_breadcrumbs":"","_seopress_robots_freeze_modified_date":"","_seopress_robots_custom_modified_date":"","_seopress_robots_canonical":"","_seopress_social_fb_title":"","_seopress_social_fb_desc":"","_seopress_social_fb_img":"","_seopress_social_fb_img_attachment_id":0,"_seopress_social_fb_img_width":0,"_seopress_social_fb_img_height":0,"_seopress_social_twitter_title":"","_seopress_social_twitter_desc":"","_seopress_social_twitter_img":"","_seopress_social_twitter_img_attachment_id":0,"_seopress_social_twitter_img_width":0,"_seopress_social_twitter_img_height":0,"_seopress_redirections_value":"","_seopress_redirections_enabled":"","_seopress_redirections_enabled_regex":"","_seopress_redirections_logged_status":"","_seopress_redirections_param":"","_seopress_redirections_type":0,"_seopress_analysis_target_kw":"","_seopress_news_disabled":"","_seopress_video_disabled":"","_seopress_video":[],"_seopress_pro_schemas_manual":[],"_seopress_pro_rich_snippets_disable_all":"","_seopress_pro_rich_snippets_disable":[],"_seopress_pro_schemas":[],"_monsterinsights_skip_tracking":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_post_was_ever_published":false},"categories":[178],"tags":[197,217,223,204,270,189],"class_list":["post-27094","post","type-post","status-publish","format-standard","hentry","category-press-releases","tag-cf-research","tag-cf-science","tag-ee-grant","tag-ee-research","tag-new-cf-research","tag-phage-therapy"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/www.emilysentourage.org\/de\/wp-json\/wp\/v2\/posts\/27094","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.emilysentourage.org\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.emilysentourage.org\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/de\/wp-json\/wp\/v2\/users\/1719"}],"replies":[{"embeddable":true,"href":"https:\/\/www.emilysentourage.org\/de\/wp-json\/wp\/v2\/comments?post=27094"}],"version-history":[{"count":5,"href":"https:\/\/www.emilysentourage.org\/de\/wp-json\/wp\/v2\/posts\/27094\/revisions"}],"predecessor-version":[{"id":27100,"href":"https:\/\/www.emilysentourage.org\/de\/wp-json\/wp\/v2\/posts\/27094\/revisions\/27100"}],"wp:attachment":[{"href":"https:\/\/www.emilysentourage.org\/de\/wp-json\/wp\/v2\/media?parent=27094"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/de\/wp-json\/wp\/v2\/categories?post=27094"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.emilysentourage.org\/de\/wp-json\/wp\/v2\/tags?post=27094"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}